We are the Rimidi.

Rimidi is a group of medical and business professionals dedicated to the delivery of serious hope for solving healthcare’s most pressing problems.

We are healthcare entrepreneurs aligned in a belief that we can do so much better, as individuals, and as an industry, in providing significant and enduring solutions.

The Rimidi leadership team is comprised of physicians, bioengineers and business professionals credited with developing technologies and practices successfully used in healthcare today.

Joshua Claman MBA

CEO

Josh Claman is a driven, experienced global executive.  He has over 25 years leading technology businesses in Asia, Europe and the Americas. His industry experiences span his time in Dell in several senior executive positions, including the founding and development of Dell’s European Healthcare business, to his role as President of ReachLocal, one of the largest advertising technology companies in the US, and serving as the Chief Business Officer of  Stratasys, a leader in 3D printing in the medical field. Josh is a strong advocate for the promise of technology.

Lucienne Marie Ide M.D., PH.D.

Founder & Chair

Lucie brings her diverse experiences in medicine, science, venture capital and technology to bear in leading Rimidi’s strategy and vision. Motivated by the belief that we can do so much better as individuals, an industry and society, Lucie left clinical medicine to join the ranks of healthcare entrepreneurs who are trying to revolutionize an industry.

Chris McIlvoy MBA

CTO

Chris is responsible for leading the overall design and development of the Rimidi product. His background includes consulting across a diverse set of verticals in a mix of strategy and engineering roles. Chris believes the primary development goal of Rimidi is to deliver technology that helps improve their daily life dealing with diabetes.

Jennifer Ide JD

General Counsel, Vice President

Jennifer has twelve years of experience advising companies about legal and regulatory risks and guiding them in business decisions. She oversees all of the Company’s legal and regulatory matters and serves as the Company’s compliance officer and HIPAA privacy and security officer. Jennifer practiced at Sutherland Asbill & Brennan before joining Rimidi.

Jim Clifford

Vice President Sales

Jim Clifford has over 22 years of experience in HIT.  Jim spent 10 years with MEDITECH, working in many facets of HIT including sales.  A founding member of the Wellcentive team, he was instrumental to the growth and success of the company.  He worked in every sector of the company including implementation, user training, project management, product design and consulting.  Most recently, Jim held the role of Strategic Sales Director for Philips Wellcentive, in which he focused on sales and business development.

Tara D. Davis MSPH

Director of Community Health

Tara, is an Epidemiologist with a diverse background in Science and Public Health. Prior to joining the Rimidi team, Tara worked as a Research Projects Manager for Emory University and the University of Alabama at Birmingham.  She holds a MSPH from UAB and a Bachelor’s of Science from Spelman College.  Tara’s expertise is in the development and evaluation of Public Health prevention programs and interventions involving technology-based approaches. She has published in the areas of Chronic Disease and Digital Health.

Cindy Gagnon RN FNP

Director of Client Success

In over 40 years as a Registered Nurse, Cindy has worn many hats.  At the beginning of her career, she worked as a Family Nurse Practitioner in a very rural part of California, and then went on to create a highly successful Occupational Medicine program for a Northern California hospital and community.  Since 2000, Cindy has found her passion in working to implement, design and support multiple healthcare software applications.  100% client satisfaction and success are what she strives for; working closely with clinicians and their technology to ensure that the technology works for the end user, not against them, by helping to improve workflow and clinical outcomes.

Mari Fonger MSN

Client Relations Manager

Mari brings over two decades of diverse healthcare experience to Rimidi. She has worked as an advanced practice nurse in both the hospital and home settings. More recently, Mari has held client-facing positions in digital health companies. She is passionate about the use of best-in-class digital therapeutics to advance the diagnosis and treatment of chronic disease. Mari is dedicated to achieving better outcomes for patients and increasing value for all healthcare stakeholders.

R William Ide, III MBA, JD

Board Member

Bill has spent his career advising corporate clients, organizations, and governmental entities on legal, regulatory, and business matters. Bill is an expert in corporate governance. He formerly served as Senior Vice President and General Counsel of Monsanto Company, President of the American Bar Association, Counsel to the United States Olympic Committee, and on the Board of Albemarle Corporation. Currently, Bill serves as a member of the Board of AFC Enterprises, chair of the Advisory Board to the Conference Board’s Governance Center, Senior Fellow and Co-Founder of Emory University’s Directors Institute, and a member of the Clark Atlanta University Board of Trustees. He is General Counsel and Secretary of the EastWest Institute, a global think-and-do tank. Bill is an experienced investor in early stage companies.

Lucienne Marie Ide M.D., PH.D.

Chairman

Lucie brings her diverse experiences in medicine, science, venture capital and technology to bear in leading Rimidi’s strategy and vision. Motivated by the belief that we can do so much better as individuals, an industry and society, Lucie left clinical medicine to join the ranks of healthcare entrepreneurs who are trying to revolutionize an industry.

Bob Bozeman

Board Member

Bob is an investor and advisor to high tech companies. He has 24 years of management experience in high-technology enterprises. He served as an officer at Wang Laboratories, contributing to growth in revenue from $50 million to $2.7 billion, and is the founder of two successful high-tech businesses (Library Systems and Bozemans’, Inc.). Bob was a General Partner with Ron Conway and Casey McGlynn in Angel Investors, LP for both Fund I and Fund II, which invested in technology companies including Ask Jeeves, AvantGo, BrightMail, Chemdex/Ventro, FindLaw, Good Technology, Google, MongoMusic, OpenTable, Opsware/LoudCloud, PayPal, RedEnvelope and Vovida Networks. Bob currently is currently General Partner of Eastlake Ventures and 530 Angels. He also serves on the Board of the public company Daegis based in Dallas.

Mark Braunstein MD

Georgia Tech University

Dr. Braunstein teaches health informatics as a graduate seminar in the college and as an elective in the Online Masters of Science in Computer Science (OMSCS) program. His latest book, Practitioners Guide to Health Informatics, a guide to health informatics for physicians and other non-technical readers, was published in the spring of 2015. His text, Contemporary Health Informatics, was published in the spring of 2014. Health Informatics in the Cloud, a brief guide to health informatics for non-technical readers, was published in 2012.

David Byrne

Former European Union Commissioner for Health and Consumer Protection

David Byrne is a lawyer by training and before entering public life spent 30 years practicing as a Barrister in the Courts of Ireland and the European Court of Justice in Luxemburg. In 1997 he was appointed Attorney General of Ireland (AG). During his term of office as AG, he was one of the negotiators of the Good Friday Agreement, which provided the political and legal framework for peace in Northern Ireland. He drafted and managed the constitutional changes necessary to give effect to the new Agreement, which were adopted by a referendum of the people in 1998

View David’s complete profile on Wikipedia.

Greg Hunter

Private Investor

Greg Hunter is a Winston-Salem, NC based businessman with an international reach in the areas of real estate, energy, hospitality, and functional beverages. Since the early 1990’s, Mr. Hunter has been involved in global asset management consulting, working with large pools of capital to effectively deploy their funds across a wide variety of strategies. More recently, he has begun to integrate the business strategies of foreign companies with US companies to promote global commerce. Additionally, he is aggregating real estate portfolios in the US, developing select properties across a variety of asset classes. Mr. Hunter serves on numerous not-for-profit and for profit boards.

Heval Mohamed Kelli MD

Katz Foundation Preventive Cardiology Fellow at Emory University

Dr. Heval Mohamed Kelli came to the US as a teenage refugee from Syria and worked as dishwasher for years to support his family and education. He is currently named the prestigious Katz foundation Fellow in Preventive Cardiology in the Emory University department of medicine. He graduated Cum Laude from Morehouse School of Medicine and he finished his internal medicine residency training with honorable distinctions in social and inpatient medicine at Emory University. Dr. Mohamed Kelli was voted resident of the year by his colleagues at Emory University in 2013. He operates several non-profit organizations focused on mentorship, healthcare outreach and medical education. His remarkable journey and story was featured on the Emory University magazine, Associated Press, NY times, CNN and Washington Post

Olivier Jarry

Global Life Sciences & Consumer Health Executive

Olivier leverages 30 years of passion improving health and living standards throughout Western/Eastern Europe, the Americas and Asia to create sustainable, profitable growth, organically and inorganically, in the Life Sciences, Consumer Health, Nutrition and Consulting industries. He assembles talented, successful and diverse teams to address unique business or societal challenges.

In 2009, when the H1N1 global pandemic flu spread globally, he redirected his team to address the needs of governments in Western and Eastern Europe. They closed the first sale for Novartis (several hundred million Euros) followed by several other ones throughout Europe and Russia/CIS.

Featured In